# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced it was selected as a spoke for ...
HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $6 price target.
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOM...
Brookline Capital analyst Kemp Dolliver downgrades Dare Bioscience (NASDAQ:DARE) from Buy to Hold.